Session Information
Session Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis
Session Type: Abstract Submissions (ACR)
Background/Purpose
Lupus nephritis (LuN) is the most common, severe manifestation of systemic lupus erythematosus (SLE). We have previously shown that glomerulonephritis appears to be a manifestation of systemic autoimmunity while tubulointerstitial inflammation (TII) is associated with additional, in situ adaptive immune cell networks that might amplify local inflammation and tissue damage. Furthermore, patients with significant TII are more likely to fail conventional therapy and progress to renal failure. Therefore, understanding the mechanisms of in situ adaptive immunity in lupus TII might provide new therapeutic opportunities for treating LuN. In mice, BCL-2 family proteins are key regulators of immune cell apoptosis and forced expression of BCL-2 in B cells promotes lupus-like nephritis. We hypothesized that dysregulated expression of the BCL-2 family proteins in human LuN TII might contribute to local adaptive immunity, inflammation and disease pathogenesis.
Methods
Frozen renal biopsy specimens from 26 patients with SLE (ISN/RPS Class III, IV or V LuN), 10 mixed cellular renal allograft rejection (MR) biopsy specimens and tonsil samples from healthy subjects and kidneys from IFNα-induced NZB/W F1 lupus mice were stained with antibodies specific for CD20, CD4, BCL-2, MCL-1 or BIM. Images were acquired using scanning laser confocal microscopy. IFNα-induced NZB/W F1 mice were treated daily with vehicle or 30 mg/kg of ABT-199 and analyzed for survival and the development of proteinuria.
Results
A recently developed imaging tool (Science Translational Medicine 2014, 6:230) was used to quantify the frequency of CD20+ B and CD4+ T cells expressing the anti-apoptotic molecules BCL-2, MCL-1 and the pro-apoptotic molecule BIM. In primary follicles of normal tonsils, both B and T cells frequently expressed BCL-2. However, upon entry into germinal centers (GC), BCL-2 was down-regulated and MCL-1 was induced. In marked contrast, in LuN and MR TII biopsies, the frequency of BCL-2+ cells was increased in B and T cells while MCL-1+ cells were rare. Observed differences between tonsil GC lymphocytes versus TII in LuN and MR for both BCL-2 and MCL-1 were highly significant (p<0.001). These expression differences were confirmed by laser capture microscopy coupled to qPCR. In contrast, the frequency of BIM+cells did not significantly vary among tissues. Consistent with these findings, BCL-2, but not MCL-1 expressing cells were detected in the inflamed kidney in IFNα-induced NZB/W F1 lupus mice. Furthermore, administration of ABT-199, a BCL-2 selective inhibitor, prevented the development of lupus nephritis by depleting intra-renal B and T cells in these animals.
Conclusion
Frequent BCL-2, but not MCL-1, expressing cells were present in LuN, MR TII tissues and IFNα-induced NZB/W F1 lupus mice. Treatment of these mice with the BCL-2 selective inhibitor ABT-199 resulted in the loss of renal B and T cells and the preservation of renal function. These data indicate that BCL-2, which is dysregulated in TII, is an attractive therapeutic target in cases of lupus nephritis manifesting tubulointerstitial inflammation.
Disclosure:
K. Ko,
None;
D. Yanez,
AbbVie,
2;
N. Kaverina,
AbbVie,
2;
V. M. Liarski,
None;
Y. Peng,
None;
L. Lan,
None;
S. Perper,
AbbVie Inc.,
3;
A. Schwartz,
AbbVie Inc.,
3;
L. O’connor,
AbbVie Inc.,
3;
A. Souers,
AbbVie Inc.,
3;
S. Elmore,
AbbVie Inc.,
3;
L. Olson,
AbbVie Inc.,
3;
M. L. Giger,
None;
L. C. Wang,
AbbVie Inc.,
3;
M. R. Clark,
AbbVie,
2.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/bcl-2-as-a-potential-therapeutic-target-in-human-lupus-tubulointerstitial-inflammation/